📢 Lys Therapeutics at the International Stroke Conference 2026

Lys Therapeutics is pleased to announce its participation in the International Stroke Conference 2026, organized by the American Heart Association, taking place in #NewOrleans 🇺🇸.

We are proud to share that our lead program, #LYS241, has been selected for an oral presentation:

• DP347 – ASA 2026
• LYS241: A Novel Humanized Antibody Counteracting tPA-Mediated Neurotoxicity and BBB Disruption in Stroke
• 🗓 Thursday, February 5, 2026 – 4:06 PM
• 🧠 Session: Neuroimmunology and Inflammation in Stroke, Novel Therapeutic Strategies

About #LYS241:

LYS241 is a first-in-class, humanized monoclonal antibody. It selectively inhibits the pathological interaction between tPA (endogenous tPA and rtPA/TNK) and NMDAr, preserving physiological receptor function while preventing excitotoxicity and blood-brain barrier disruption.

Key findings to be presented:

• Robust efficacy in NMDA-induced excitotoxicity and thromboembolic MCAo models
• Significant reduction in lesion volume
• Improved functional recovery and enhanced recanalization
• Strong activity both as monotherapy and in combination with alteplase (#rtPA) or tenecteplase (#TNK)
• Efficacy across both early and extended therapeutic windows
• Strong safety profile, including no alteration of physiological NMDAr function

By neutralizing #excitotoxicity and #BBB disruption triggered by endogenous and exogenous tPA, LYS241 demonstrates strong therapeutic potential as a standalone therapy or in combination with #thrombolysis and/or #thrombectomy.

LYS241 is currently advancing through IND/CTA-enabling studies in preparation for first-in-human clinical development.

Our CEO, Dr. Manuel Blanc, looks forward to engaging with the stroke and neurovascular community in New Orleans.

#ISC2026 #StrokeResearch #Stroke #Neuroinflammation #NeuroImmunology #BloodBrainBarrier #TranslationalScience #Biotech #LysTherapeutics #LYS241